Rachel Craig
Family · Butler, PANPI 1225516321
Payments from drug & device makers
Across 273 payments — averaging $23.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cequr Corporation$2K
- Novo Nordisk$969
- Lilly USA, LLC$728
- Boehringer Ingelheim$418
- Dexcom, Inc.$246
- Medtronic$243
- plus $2K from 31 others
What the payments were for
- Food & beverage$6,26499%
- Education$781%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cequr Corporation | 4 | $1,721 |
| Novo Nordisk | 61 | $969 |
| Lilly USA, LLC | 51 | $728 |
| Boehringer Ingelheim | 21 | $418 |
| Dexcom, Inc. | 19 | $246 |
| Medtronic | 5 | $243 |
| Amgen(2 entities) | 12 | $215 |
| AbbVie | 10 | $170 |
| Bayer | 8 | $160 |
| Sanofi-aventis U.S. LLC | 9 | $155 |
| Tandem Diabetes Care, Inc. | 9 | $148 |
| BETA Bionics, Inc. | 6 | $95 |
| Insulet Corporation | 5 | $93 |
| Abbott | 5 | $92 |
| AstraZeneca(2 entities) | 5 | $84 |
| Amneal Pharmaceuticals LLC | 4 | $84 |
| Antares Pharma, Inc. | 5 | $79 |
| Xeris Pharmaceuticals, Inc. | 4 | $77 |
| Radius Health, Inc. | 3 | $63 |
| Neurocrine Biosciences, Inc. | 3 | $59 |
| Currax Pharmaceuticals LLC | 3 | $59 |
| IBSA Pharma Inc. | 3 | $57 |
| Ascendis Pharma Endocrinology Inc | 2 | $36 |
| Kyowa Kirin, Inc. | 2 | $32 |
| BD | 1 | $31 |
| Johnson & Johnson | 1 | $29 |
| Amarin Pharma, Inc. | 2 | $29 |
| Madrigal Pharmaceuticals | 1 | $22 |
| Cochlear Americas | 1 | $22 |
| Embecta Corp. | 1 | $20 |
| Globus Medical | 1 | $18 |
| Lifescan, Inc. | 1 | $18 |
| Sequel Med Tech, LLC | 1 | $17 |
| Amphastar Pharmaceuticals, Inc. | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $14 |
| Merck | 1 | $13 |
| Theracosbio, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$1,647
- INPEN SMART INSULIN DELIVERY SYSTEM$156
- Ozempic$114
- JARDIANCE$101
How this compares
$6,342 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 827 | $929,759 |
| TrulicityDulaglutide | 406 | $496,221 |
| JardianceEmpagliflozin | 474 | $414,131 |
| MounjaroTirzepatide | 320 | $377,919 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 106 | $70,449 |
| Tresiba Flextouch U-100Insulin Degludec | 76 | $62,792 |
| Tresiba Flextouch U-200Insulin Degludec | 60 | $51,478 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 70 | $49,081 |
| Humalog Kwikpen U-200Insulin Lispro | 30 | $43,873 |
| Humalog Kwikpen U-100Insulin Lispro | 126 | $41,492 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $35,997 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 67 | $34,990 |
| FarxigaDapagliflozin Propanediol | 53 | $34,951 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 233 | $31,045 |
| Novolog FlexpenInsulin Aspart | 108 | $28,855 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $969 | $946,187871 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $728 | $882,694751 claims |
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr | $418 | $434,313501 claims |
| AstraZenecaFarxiga | $84 | $34,95153 claims |
| Johnson & JohnsonInvokana | $29 | $19,04921 claims |
| AmgenProlia | $215 | $17,99211 claims |
| MerckJanuvia | $13 | $14,95111 claims |
| AbbVieSynthroid | $170 | $8,703130 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $84 | $5,482434 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.
Other family in Butler
- Margaret SpingolaButler$19K
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.